Suzhou
688266.SSSuzhou Zelgen Biopharmaceuticals Co., Ltd. Price (688266.SS)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
255,580,499
(6.4919)%Income Statement Summary
| Revenue | |
| Cost of Revenue | |
| Gross Profit | |
| Operating Expenses | |
| Operating Income | |
| Other Expenses | |
| Net Income |
Income Statement
Suzhou Zelgen Biopharmaceuticals Co., Ltd.Currency: CNY
| YEAR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
200,334.00
+0% |
0.00
+0% |
1,311,158.00
+0% |
0.00
+0% |
27,660,909.00
+0% |
190,360,565.00
+588% |
302,305,057.00
+59% |
386,438,784.00
+28% |
|||||||||||
| Cost of Revenue | |||||||||||||||||||
| Cost of Revenue | 159,800.00 | 5,087,100.00 | 893,903.00 | 33,268,210.00 | 27,476.00 | 6,268,583.00 | 26,161,022.00 | 31,422,727.00 | |||||||||||
| Gross Profit | |||||||||||||||||||
| Gross Profit |
40,534.00
+0% |
-5,087,100.00
-12,650% |
417,255.00
-108% |
-33,268,210.00
-8,073% |
27,633,433.00
-183% |
184,091,982.00
+566% |
276,144,035.00
+50% |
355,016,057.00
+29% |
|||||||||||
| Gross Profit Ratio | (0.20%) | (0.00%) | (0.32%) | (0.00%) | (1.00%) | (0.97%) | (0.91%) | (0.92%) | |||||||||||
| Operating Expenses | |||||||||||||||||||
| Research and Development | 61,077,401.00 | 158,822,535.00 | 142,805,223.00 | 183,841,536.00 | 314,198,309.00 | 509,394,274.00 | 497,725,871.00 | 496,329,685.00 | |||||||||||
| General and Administrative | 73,625,837.00 | 7,576,050.00 | 312,602,103.00 | 246,940,869.00 | 43,227,145.00 | 51,605,502.00 | 53,889,193.00 | -18,100,168.58 | |||||||||||
| Selling, General & Admin... | 73,625,837.00 | 7,576,050.00 | 312,602,103.00 | 254,770,768.00 | 78,297,105.00 | 191,347,995.00 | 281,574,541.00 | 100,410,308.00 | |||||||||||
| Selling & Marketing Exp... | 0.00 | 0.00 | 0.00 | 7,829,898.00 | 35,069,959.00 | 139,742,493.00 | 227,685,348.00 | 119,404,732.00 | |||||||||||
| Depreciation and Amortiz... | 5,733,200.00 | 5,087,100.00 | 14,083,000.00 | 33,268,210.00 | 46,704,140.00 | 53,393,010.00 | 70,806,070.00 | 54,829,798.00 | |||||||||||
| Other Expenses | 5,365,137.00 | -1,149.93 | -10,000.00 | 1,655,602.00 | -6,826,365.78 | -14,019,368.87 | 666,993.00 | 0.00 | |||||||||||
| Total Operating Expenses | 134,966,312.00 | 148,326,096.00 | 446,101,491.00 | 440,267,907.00 | 385,669,049.00 | 686,722,901.00 | 779,967,406.00 | 652,798,454.00 | |||||||||||
| Cost and Exponses | 135,126,113.00 | 148,326,096.00 | 446,995,394.00 | 440,267,907.00 | 385,696,525.00 | 692,991,485.00 | 806,128,429.00 | 684,221,182.00 | |||||||||||
| Operating Income | |||||||||||||||||||
| Operating Income |
-133,633,005.56
+0% |
-146,467,298.13
+10% |
-442,647,860.70
+202% |
-439,788,510.54
-1% |
-358,035,616.39
-19% |
-502,630,919.49
+40% |
-503,823,371.70
+0% |
-408,794,850.00
-19% |
|||||||||||
| Operating Income Ratio | (-667.05%) | (0.00%) | (-337.60%) | (0.00%) | (-12.94%) | (-2.64%) | (-1.67%) | (-1.06%) | |||||||||||
| Other Income and Exp... | |||||||||||||||||||
| Interest Income | 1,290,520.00 | 1,931,145.00 | 879,366.00 | 1,167,194.00 | 38,339,607.00 | 39,977,624.00 | 28,745,441.00 | 39,354,994.00 | |||||||||||
| Interest Expenses | 0.00 | 0.00 | 30,612.00 | 1,159,999.00 | 1,088,146.00 | 4,417,201.00 | 12,031,551.00 | 24,451,686.00 | |||||||||||
| Total Other Income/Exp... | 5,365,137.00 | -1,150.06 | -10,000.00 | 906.54 | -4,576.00 | -6,102,926.00 | -2,397,235.00 | 109,710,339.00 | |||||||||||
| EBITDA | |||||||||||||||||||
| EBITDA | -129,192,571.66 | -141,381,343.00 | -437,351,347.40 | -405,002,339.00 | -256,629,539.00 | -405,553,834.00 | -402,207,120.00 | -214,226,485.00 | |||||||||||
| EBITDA ratio | (-644.66%) | (0.00%) | (-329.35%) | (0.00%) | (-9.90%) | (-2.14%) | (-1.36%) | (-0.55%) | |||||||||||
| Income Before Tax | |||||||||||||||||||
| Income Before Tax | -128,267,868.56 | -146,468,448.06 | -442,657,860.70 | -439,787,607.29 | -304,832,774.03 | -465,147,215.39 | -487,954,729.84 | -299,084,511.00 | |||||||||||
| Income Before Tax Ratio | (-640.27%) | (0.00%) | (-337.61%) | (0.00%) | (-11.02%) | (-2.44%) | (-1.61%) | (-0.77%) | |||||||||||
| Income Tax Expense | |||||||||||||||||||
| Income Tax Expense | 44,318.00 | -56,989.58 | -780,375.50 | 8,195,956.00 | 5,842,563.00 | -3,156,392.88 | -2,005,371.74 | -3,949,557.00 | |||||||||||
| Net Income | |||||||||||||||||||
| Net Income | -128,267,868.56
+0% |
-146,468,448.06
+14% |
-440,089,014.69
+200% |
-447,983,564.07
+2% |
-310,675,338.01
-31% |
-461,990,822.51
+49% |
-485,949,358.10
+5% |
-278,582,744.00
-43% |
|||||||||||
| Net Income Ratio | (-640.27%) | (0.00%) | (-335.65%) | (0.00%) | (-11.23%) | (-2.43%) | (-1.61%) | (-0.72%) | |||||||||||
| Earning Per Share | |||||||||||||||||||
| Basic EPS | -0.71 | -0.81 | -2.45 | -1.87 | -1.29 | -1.92 | -2.02 | -1.09 | |||||||||||
| Diluted EPS | -0.71 | -0.81 | -2.45 | -1.87 | -1.29 | -1.92 | -2.02 | -1.09 | |||||||||||
| Share Outstanding | |||||||||||||||||||
| Basic Share Outstanding | 179,718,770.00 | 179,718,770.00 | 179,718,770.00 | 240,000,000.00 | 240,000,000.00 | 240,000,000.00 | 240,000,000.00 | 255,580,499.00 | |||||||||||
| Diluted Share Outstanding | 179,718,770.00 | 179,718,770.00 | 179,718,770.00 | 240,000,000.00 | 240,000,000.00 | 240,000,000.00 | 240,000,000.00 | 255,580,499.00 | |||||||||||